Table 2 Summary of the pooled safety outcome
Outcome or subgroup | Studies | Cases | No. with event/total no. of patients INIs and EFV | Effect estimate (RR and 95% CI) |
|---|---|---|---|---|
Any AEs | 2 | 215 | 98/120 and 86/95 | 0.92 (0.76,1.11) |
 DTG vs. EFV | 1 | 113 | 52/69 and 40/44 | 0.83 (0.70,0.98) |
 RAL vs. EFV | 1 | 102 | 46/51 and 46/51 | 1.00 (0.88,1.14) |
Drug-related AEs | 3 | 674 | 50/349 and 54/325 | 0.80 (0.57,1.14) |
 DTG vs. EFV | 1 | 113 | 19/69 and 14/44 | 0.87 (0.49,1.54) |
 RAL vs. EFV | 2 | 561 | 31/280 and 40/281 | 0.78 (0.50,1.21) |
Discontinuation for drugs | 3 | 674 | 2/349 and 8/325 | 0.30 (0.08,1.09) |
 DTG vs. EFV | 1 | 113 | 0/69 and 2/44 | 0.13 (0.01,2.62) |
 RAL vs. EFV | 2 | 561 | 2/280 and 6/281 | 0.39 (0.09,1.64) |
Grade 3–4 AEs | 3 | 674 | 78/349 and 87/325 | 0.89 (0.68,1.15) |
 DTG vs. EFV | 1 | 113 | 3/69 and 2/44 | 0.96 (0.17,5.50) |
 RAL vs. EFV | 2 | 561 | 75/280 and 85/281 | 0.89 (0.68,1.15) |
IRIS (Grade 3–4) | 3 | 674 | 13/349 and 20/325 | 0.63 (0.32,1.25) |
 DTG vs. EFV | 1 | 113 | 1/69 and 1/44 | 0.64 (0.04,9.93) |
 RAL vs. EFV | 2 | 561 | 12/280 and 19/281 | 0.63 (0.31,1.28) |
Death | 3 | 672 | 13/350 and 16/322 | 0.80 (0.39,1.64) |
 DTG vs. EFV | 1 | 113 | 0/69 and 0/44 | NA |
 RAL vs. EFV | 2 | 559 | 13/281 and 16/278 | 0.80 (0.39,1.64) |